Top Therapeutic Areas in Expedited Pathways in 2026

Oncology

Cancer therapies continue to dominate Fast Track, Breakthrough Therapy Designation (BTD), Priority Review, Accelerated Approval, and Orphan Drug Designation activity.

This is driven by:

  • High unmet medical need
  • Biomarker-driven precision therapies
  • Strong surrogate endpoints supporting accelerated approval
  • High orphan designation overlap in rare cancers

Examples from 2026 include:

  • LP-284 for soft tissue sarcomas (Orphan Drug Designation)
  • NP-G2-044 for pancreatic cancer (Orphan Drug Designation)
  • Multiple March 2026 Fast Track and Priority Review decisions across brain, lung, ovarian, and hematologic cancers

FDA and industry analyses also continue to show oncology as the largest therapeutic area for new approvals and expedited pathways. In 2025, oncology accounted for approximately 28% of novel FDA approvals, and this trend has continued into 2026.

“Oncology continues to dominate FDA innovation pathways, accounting for nearly 28% of novel approvals in 2025, with its leadership in new approvals and expedited designations extending strongly into 2026”
“FDA’s 2026 ARC program and individualized therapy framework highlight a strong regulatory push toward accelerating treatments for ultra-rare diseases.”

Rare Diseases / Ultra-Rare Genetic Disorders

Rare disease therapies are the second major leader, especially with:

  • orphan drug designations
  • rare pediatric disease pathways
  • gene and cell therapies
  • individualized therapies

Examples:

  • Menkes disease
  • Arginase 1 Deficiency
  • Achondroplasia
  • Duchenne muscular dystrophy
  • ultra-rare pediatric disorders

FDA’s 2026 ARC program and individualized therapy framework strongly emphasize ultra-rare disease acceleration.

Haematology

Especially strong in:

  • leukemia
  • lymphoma
  • hemophilia
  • sickle cell disease
  • bone marrow disorders

Many haematology drugs receive multiple concurrent designations such as: Fast Track + Breakthrough + Priority Review + Orphan.

“In 2026, hematology ranked third for expedited designations, with leukemia, lymphoma, hemophilia, and sickle cell therapies receiving multiple regulatory pathways.”
“In 2026, Neurology/CNS ranked fourth for expedited designations, driven by Alzheimer’s, glioma, schizophrenia, bipolar disorder, and rare neurodegenerative diseases.”

Neurology / CNS

Growing activity in:

  • Alzheimer’s disease
  • glioma
  • schizophrenia
  • bipolar disorder
  • neurodegenerative rare diseases

Examples include CNS approvals and expedited reviews for rare neurological disorders and brain tumors.

Immunology / Inflammation

Increasing designations for:

  • autoimmune diseases
  • dermatology biologics
  • chronic inflammatory diseases
  • fibrosis and immuno-oncology overlaps

Examples include:

  • atopic dermatitis
  • primary biliary cholangitis
  • graft-versus-host disease
“In 2026, Immunology/Inflammation ranked as the fifth major category for expedited designations, driven by rising activity in autoimmune diseases, dermatology biologics, chronic inflammatory conditions, and fibrosis-related disorders.”

Overall Trend

A major pattern in 2026 is that Oncology + Rare Disease overlap heavily, meaning many oncology drugs are also orphan-designated therapies. FDA analyses show orphan products account for a large share of breakthrough and priority review pathways, making these two segments the dominant force in expedited approvals.

Pharma Insight Reports

https://adisinsight.springer.com/insight-hub